换一批
换一批Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
作者：
主题词
青少年(Adolescent);成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯甲酰胺类(Benzamides);无病生存(Disease-Free Survival);女(雌)性(Female);随访研究(Follow-Up Studies);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);核型分析(Karyotyping);男(雄)性(Male);中年人(Middle Aged);费城染色体(Philadelphia Chromosome);哌嗪类(Piperazines);前体细胞淋巴母细胞白血病淋巴瘤(Precursor Cell Lymphoblastic Leukemia-Lymphoma);试验预期值(Predictive Value of Tests);嘧啶类(Pyrimidines);复发(Recurrence);存活率(Survival Rate);移植, 同种(Transplantation, Homologous)
DOI
10.3324/haematol.11891
PMID
18223280
发布时间
2015-11-19
- 浏览8
Haematologica
287-90页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
